Ionis Pharmaceuticals Inc. (NASDAQ:IONS) SVP Elizabeth L. Hougen sold 5,000 shares of the stock in a transaction on Friday, November 11th. The stock was sold at an average price of $39.75, for a total value of $198,750.00. Following the transaction, the senior vice president now directly owns 9,048 shares in the company, valued at approximately $359,658. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of Ionis Pharmaceuticals Inc. (NASDAQ:IONS) opened at 47.49 on Tuesday. Ionis Pharmaceuticals Inc. has a 52 week low of $19.59 and a 52 week high of $63.71. The stock’s 50 day moving average price is $32.12 and its 200 day moving average price is $30.18. The firm’s market capitalization is $5.76 billion.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Wednesday, November 9th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.08 by $0.02. Ionis Pharmaceuticals had a negative return on equity of 120.60% and a negative net margin of 77.30%. The firm had revenue of $110.90 million for the quarter, compared to analysts’ expectations of $114.65 million. The company’s revenue for the quarter was up 125.9% on a year-over-year basis. On average, analysts predict that Ionis Pharmaceuticals Inc. will post ($1.11) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

A number of brokerages have weighed in on IONS. Leerink Swann reissued a “market perform” rating and set a $36.00 price target (up previously from $26.00) on shares of Ionis Pharmaceuticals in a research note on Tuesday, August 2nd. Zacks Investment Research raised Ionis Pharmaceuticals from a “sell” rating to a “hold” rating and set a $41.00 price target on the stock in a research note on Wednesday, August 3rd. Cowen and Company reissued a “buy” rating on shares of Ionis Pharmaceuticals in a research note on Wednesday, August 3rd. Piper Jaffray Cos. reissued a “buy” rating on shares of Ionis Pharmaceuticals in a research note on Wednesday, November 9th. Finally, Barclays PLC increased their price target on Ionis Pharmaceuticals from $26.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Tuesday, August 2nd. Four analysts have rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $41.85.

Large investors have recently modified their holdings of the stock. Metropolitan Life Insurance Co. NY raised its stake in shares of Ionis Pharmaceuticals by 0.9% in the second quarter. Metropolitan Life Insurance Co. NY now owns 9,055 shares of the company’s stock worth $211,000 after buying an additional 82 shares during the period. IBM Retirement Fund raised its stake in shares of Ionis Pharmaceuticals by 0.9% in the second quarter. IBM Retirement Fund now owns 12,162 shares of the company’s stock worth $283,000 after buying an additional 110 shares during the period. Commerzbank Aktiengesellschaft FI raised its stake in shares of Ionis Pharmaceuticals by 1.6% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 8,966 shares of the company’s stock worth $209,000 after buying an additional 140 shares during the period. Checchi Capital Advisers LLC raised its stake in shares of Ionis Pharmaceuticals by 0.9% in the third quarter. Checchi Capital Advisers LLC now owns 22,185 shares of the company’s stock worth $813,000 after buying an additional 192 shares during the period. Finally, Principal Financial Group Inc. raised its stake in shares of Ionis Pharmaceuticals by 1.5% in the third quarter. Principal Financial Group Inc. now owns 25,251 shares of the company’s stock worth $925,000 after buying an additional 380 shares during the period. 88.35% of the stock is owned by institutional investors.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc, formerly Isis Pharmaceuticals, Inc, is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform.

5 Day Chart for NASDAQ:IONS

Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.